美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MNSN HLDGS INC.

54.00

0.0000

成交量：- -

成交額：- -

市值：32.02億

市盈率：2.13

高：54.00

開：54.00

低：54.00

收：54.00

52周最高：60.00

52周最低：35.00

股本：5,929.09萬

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):25.35

每股收益(LYR):25.35

淨資產收益率：9.78%

總資產收益率：0.76%

市淨率：0.26

市盈率(LYR):2.13

資料載入中...

總覽公司新聞資訊公告

Aktis Oncology 獲得禮來作為擴大美國 IPO 規模的主要投資者

Aktis Oncology申請美國IPO，生物技術公司上市反彈

BUZZ-Tenaya Therapeutics 推出股票後業績下滑

BUZZ-抗體療法顯示出治療罕見血癌的潛力後，Incyte 公司業績上升

BUZZ-藥物開發商貝萊特生物公司因計劃股本募集而下跌

BUZZ--美國股票走勢-阿里巴巴、百健、全球風險投資公司

BUZZ-券商觀點：雅培收購 Exact Sciences 後，券商下調其評級

BUZZ-Arcus Biosciences 因股票發行上市而下跌

BUZZ-2.25 億美元股票交易後，MindMed 下跌

BUZZ-在罕見眼癌試驗中，聯合用藥顯示出生存優勢，Ideaya 公司業績上升

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MNSH/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MNSH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MNSH\",,,,,undefined,":{"symbol":"MNSH","market":"US","secType":"STK","nameCN":"MNSN HLDGS INC.","latestPrice":54,"timestamp":1776283200000,"preClose":54,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":59290865,"eps":25.35,"marketStatus":"未開盤","change":0,"latestTime":"04-15 16:00:00 EDT 延時","open":54,"high":54,"low":54,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":25.35,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1776326400000},"marketStatusCode":0,"adr":0,"exchange":"GREY","adjPreClose":54,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MNSH\",,,,,undefined,":{"symbol":"MNSH","floatShares":0,"roa":"0.76%","roe":"9.78%","lyrEps":25.35,"shares":59290865,"dividePrice":0,"high":54,"amplitude":0,"preClose":54,"low":54,"week52Low":35,"pbRate":"0.26","psRate":"0.55","week52High":60,"institutionHeld":0,"latestPrice":54,"eps":25.35,"divideRate":0,"volume":0,"delay":15,"ttmEps":25.35,"open":54,"prevYearClose":59,"prevWeekClose":54,"prevMonthClose":54,"prevQuarterClose":54,"fiveDayClose":54,"twentyDayClose":54,"sixtyDayClose":59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MNSH\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MNSH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MNSH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MNSH\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2601808438","title":"Aktis Oncology 獲得禮來作為擴大美國 IPO 規模的主要投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808438","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808438?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 20:37","pubTimestamp":1767789453,"startTime":"0","endTime":"0","summary":"更新版 3-Aktis Oncology 获得礼来作为扩大美国 IPO 规模的主要投资者第 5-6 段增加了分析师评论Arasu Kannagi Basil. 路透1月7日 - 癌症药物开发商Aktis Oncology周三表示，该公司扩大首次公开募股规模的目标估值高达9.454亿美元，这表明投资者对2026年该公司首次在美国上市的需求强劲。礼来此举的基础是其与 Aktis 于 2024 年达成的开发肿瘤靶向放射性药物的合作关系。Aktis 公司正在开发治疗多种实体瘤的药物。Aktis Oncology公司将在纳斯达克上市，股票代码为 \"AKTS\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL4T3Y80U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","LU2211815571.USD","IE00B4R5TH58.HKD","IE00B7SZLL34.SGD","LU2324357040.USD","LU1366192091.USD","LU1670711040.USD","LU1261432733.SGD","BK4581","LU2106854487.HKD","LU2168564149.EUR","IE0001KFT4U8.USD","LU1074936037.SGD","LU2168564065.EUR","LU0980610538.SGD","LU1323610961.USD","SG9999014880.SGD","LU0868494617.USD","LU0689472784.USD","LU1989771016.USD","BAC","SG9999018857.SGD","LU2089984988.USD","IE0002141913.USD","LU2264538146.SGD","SG9999018865.SGD","LU2746668461.USD","SG9999015952.SGD","LU0354030511.USD","LU0256863902.USD","LU0466842654.USD","LU0943347566.SGD","MNSH","LU0203345920.USD","LU1162221912.USD","LU2168563687.JPY","LLY","LU0289739699.SGD","LU2237443465.HKD","LU0109391861.USD","LU2125154935.USD","LU1280957306.USD","IE0005OL40V9.USD","LU0130103400.USD","LU1267930730.SGD","IE00B4JS1V06.HKD","LU0106261372.USD","LU1894683348.USD","BMY","LU1127390331.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592118027","title":"Aktis Oncology申請美國IPO，生物技術公司上市反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118027","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592118027?lang=zh_tw&edition=fundamental","pubTime":"2025-12-20 06:45","pubTimestamp":1766184351,"startTime":"0","endTime":"0","summary":"Aktis Oncology申请美国IPO，生物技术公司上市反弹路透12月19日 - Aktis Oncology公司周五在美国提交了首次公开募股申请，生物技术行业的股市上市在经历了放缓后出现反弹。Aktis Oncology 公司由生物技术投资者托德-福里于 2020 年 8 月共同创立，目前正在开发治疗多种实体瘤的药物。Aktis Oncology 的主要候选药物 AKY-1189 正在进行早期研究，以治疗某些实体瘤，包括一种晚期膀胱癌、乳腺癌和结直肠癌。Aktis Oncology 公司的前身是 HotKnot Therapeutics 公司，将在纳斯达克上市，股票代码为 \"AKTS\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL4T3XP1JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861165.SGD","BK4585","IE0001KFT4U8.USD","LBRX","LU2129689431.USD","LU1791807156.HKD","LU0208291251.USD","LU0306807586.USD","LU0052756011.USD","IE00BZ1G4Q59.USD","LU1880398554.USD","LU1363072403.SGD","LU0130517989.USD","BK4553","LU0310800965.SGD","IE00B7SZLL34.SGD","LU0648000940.SGD","LU0321505439.SGD","LU1069347547.HKD","LU0234572021.USD","LU1074936037.SGD","LU1035773651.USD","IE00BKVL7J92.USD","LU1201861249.SGD","MNSH","BAC","LU0980610538.SGD","BK4534","LU0203347892.USD","EVMN","LU0130103400.USD","LU1668664300.SGD","LU1804176565.USD","IE00BLSP4452.SGD","LU0128525689.USD","LU1883839398.USD","LU1894683348.USD","LU0256863811.USD","LU0306806265.USD","LU0477156797.USD","LU0256863902.USD","LU0648001328.SGD","LU1162221912.USD","OWL","LU2129689514.USD","IE0034235188.USD","LU0130102774.USD","LU0320765489.SGD","IE00BBT3K403.USD","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590440215","title":"BUZZ-Tenaya Therapeutics 推出股票後業績下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2590440215","media":"路透中文","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590440215?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 06:25","pubTimestamp":1765491942,"startTime":"0","endTime":"0","summary":"BUZZ-Tenaya Therapeutics 推出股票后业绩下滑12月11日 - ** 药物开发商Tenaya Therapeutics的TNYA.O股价在延时交易中下跌12.5%至1.19美元** TNYA在  公开发行普通股和认股权证；规模未披露** Leerink Partners和Piper Sandler担任此次发行的联合账簿管理人** 另外，TNYA公司宣布对罕见心脏病进行基因治疗的早期试验数据 。** 覆盖该股的所有八家券商均给予 \"买入 \"或更高评级；PT中位数为5美元--数据由LSEG编制** 截至上次收盘，TNYA股价年累计下跌4.9%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL4S3XH1L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","TNYA","BK4207","BK4127","BK4539","BK4139","MNSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589648337","title":"BUZZ-抗體療法顯示出治療罕見血癌的潛力後，Incyte 公司業績上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2589648337","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589648337?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 19:49","pubTimestamp":1765194570,"startTime":"0","endTime":"0","summary":"BUZZ-抗体疗法显示出治疗罕见血癌的潜力后，Incyte 公司业绩上升12月8日 - ** 制药商Incyte INCY.O股价盘前上涨2.4%，报105美元 ** INCY周日表示，其试验性抗体疗法INCA033989显示，一种罕见血癌患者的脾脏大小和症状明显减轻。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4T3XE0RQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4550","MNSH","INCY","BK4532","BK4585","BK4207","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588470583","title":"BUZZ-藥物開發商貝萊特生物公司因計劃股本募集而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2588470583","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588470583?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 05:43","pubTimestamp":1764625393,"startTime":"0","endTime":"0","summary":"12月1日 - ** 药物开发商贝莱特生物公司BLTE.O股价在延时交易中下跌1.3%，至152美元** BLTE 宣布  公开发售美国存托股票；规模未披露** 出售股票所得资金将用于商业化准备和开发管线等用途** 摩根士丹利、Leerink Partners、BofA Securities 和 Cantor 是此次发行的联合积极簿记管理人** BLTE 公司治疗一种罕见遗传性眼病的实验性药物在一项后期研究中达到了主要目标 ，该公司股价周一创下历史新高，收盘上涨  12%，报 154.02 美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL4S3X71PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LU0130103400.USD","IE00B19Z3581.USD","BAC","BK4559","LU0980610538.SGD","LU1894683264.USD","LU2129689431.USD","IE00B1BXHZ80.USD","BK4516","LU0234572021.USD","LU0158827781.USD","IE00BZ1G4Q59.USD","LU0106831901.USD","LU1366192091.USD","LU0795875169.SGD","LU0256863902.USD","LU2357305700.SGD","LU0006306889.USD","LU1880398554.USD","IE0001KFT4U8.USD","LU0683600562.USD","LU1989772923.USD","LU0149725797.USD","LU1791807156.HKD","LU0203347892.USD","LU2347655156.SGD","LU0795875086.SGD","IE00BLSP4239.USD","LU1496350171.SGD","LU1718418525.SGD","LU0052756011.USD","MNSH","LU0130102774.USD","LU0158827948.USD","IE00BLSP4452.SGD","LU0477156797.USD","LU0267386448.USD","BK4588","LU1804176565.USD","IE00BKVL7J92.USD","IE00BBT3K403.USD","BK4585","LU2089283258.USD","BK4553","LU0256863811.USD","LU0306806265.USD","LU0070302665.USD","LU1162221912.USD","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585464196","title":"BUZZ--美國股票走勢-阿里巴巴、百健、全球風險投資公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2585464196","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585464196?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 20:43","pubTimestamp":1763988219,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nL4T3X00MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0143863198.USD","LU0577902611.USD","LU1316542783.SGD","LU1642822792.SGD","LU0197773673.USD","LU1242518857.USD","BK4532","HBBD.SI","89988","LU0306807586.USD","LU1211504680.USD","LU0823426480.USD","LU0531970944.HKD","LU0320765992.SGD","LU3063872942.SGD","MNSH","CLSDQ","LU1880383440.USD","LU0589944569.HKD","LU1880398554.USD","09988","CLSD","LU0417516738.SGD","BIIB","LU0821914370.USD","LU1688375341.USD","LU2097828631.EUR","ALBmain","LU0011963245.USD","BMY","LU0261950983.USD","LU0577902454.USD","LU0321505439.SGD","LU1188198961.HKD","LU1430594728.SGD","VG","LU0611395673.USD","IE0009355771.USD","LU0516422952.EUR","LU0630378429.USD","BK4139","BK1608","LU0456846285.SGD","LU1051768304.USD","LU0516423174.USD","IE00B543WZ88.USD","BABA","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2585432891","title":"BUZZ-券商觀點：雅培收購 Exact Sciences 後，券商下調其評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2585432891","media":"路透中文","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585432891?lang=zh_tw&edition=fundamental","pubTime":"2025-11-21 21:09","pubTimestamp":1763730558,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：雅培收购 Exact Sciences 后，券商下调其评级11月21日 - ** 癌症测试制造商Exact Sciences EXAS.O周四表示，医疗设备制造商雅培实验室ABT.N将以230亿美元的价格收购该公司，交易 。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nL4T3WX0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU0477156953.USD","BK4207","LU0130102774.USD","IE00B4R5TH58.HKD","LU0128525689.USD","LU1061106388.HKD","LU2133065610.SGD","SG9999004303.SGD","ABT","LU1989763690.USD","LU1914381329.SGD","LU1023059063.AUD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0114720955.EUR","SGXZ23171101.USD","BK4533","LU2360032135.SGD","LU1668664300.SGD","MNSH","LU2211815571.USD","LU0648001328.SGD","IE0002141913.USD","LU1267930227.SGD","LU1244550577.SGD","BK4548","LU0310800965.SGD","LU0170899867.USD","LU2125154778.USD","IE00BSNM7G36.USD","SG9999002232.USD","LU1691799644.USD","LU0289739699.SGD","LU0320765646.SGD","LU0052756011.USD","LU0098860793.USD","LU1244550221.USD","BK4534","EXAS","LU1721429402.USD","LU0980610538.SGD","LU1861559042.SGD","IE00B2B36J28.USD","BK4585","LU0130517989.USD","IE00BFTCPJ56.SGD","SG9999002224.SGD","IE0009355771.USD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579839108","title":"BUZZ-Arcus Biosciences 因股票發行上市而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2579839108","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579839108?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 04:58","pubTimestamp":1761857883,"startTime":"0","endTime":"0","summary":"** Arcus Biosciences RCUS.N股价盘后下跌 5.7%，报 19.05 美元，该公司正寻求股票融资。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL4T3WB30C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0742534661.SGD","LU2237438978.USD","LU0061475181.USD","BK4588","LU1668664300.SGD","LU0251142724.SGD","LU2471134879.HKD","LU2265009873.SGD","LU0345770308.USD","RCUS","BK4552","LU1868836914.USD","LU1868836757.USD","LU1868837136.USD","LU2237443465.HKD","LU1791807156.HKD","IE0002270589.USD","LU2237443895.HKD","LU1868837300.USD","BK4139","LU0048573561.USD","IE00B19Z3581.USD","LU0106831901.USD","LU0251131958.USD","LU2750360997.AUD","LU2237443382.USD","IE00BFXG1179.USD","IE0004086264.USD","IE0034235188.USD","LU1894683348.USD","BK4127","IE0004091025.USD","LU1868836591.USD","IE00B19Z3B42.SGD","LU2471134523.USD","BK4533","IE00BSNM7G36.USD","LU1894683264.USD","MNSH","LU2237443549.SGD","BK4516","LU1804176565.USD","LU2750360641.GBP","LU0096364046.USD","BK4585","LU0345770993.USD","LU2471134796.USD","BK4550","LU2471134952.CNY","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579495311","title":"BUZZ-2.25 億美元股票交易後，MindMed 下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2579495311","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579495311?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 20:19","pubTimestamp":1761826746,"startTime":"0","endTime":"0","summary":"BUZZ-2.25 亿美元股票交易后，MindMed 下跌10月30日 - ** Mind MedicineMNMD.O股价盘前下跌 3.2%，收于 12.50 美元，此前该公司在一夜之间完成了 2.25 亿美元的后续定价。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL4S3WB1V6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVR","BK4007","BK4207","MNMD","BK4127","BK4559","JEF","MNSH","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2576587853","title":"BUZZ-在罕見眼癌試驗中，聯合用藥顯示出生存優勢，Ideaya 公司業績上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2576587853","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576587853?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 18:53","pubTimestamp":1760957631,"startTime":"0","endTime":"0","summary":"BUZZ-在罕见眼癌试验中，联合用药显示出生存优势，Ideaya 公司业绩上升10月20日 - ** 加州药物开发商Ideaya BiosciencesIDYA.O股价盘前上涨7.3%至31.40美元** 该公司称，在一项中期研究中，接受 darovasertib和辉瑞的Xalkori组合治疗 的罕见眼癌患者 的中位总生存期为21.1个月** 根据已公布的数据，转移性葡萄膜黑色素瘤的生存期通常为12个月左右 - IDYA** 中位生存期是指患某种疾病的患者中，50%仍然存活，50%已经死亡的时间长度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nL4S3W109O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999013999.USD","BK4585","MNSH","LU0170899867.USD","BK4550","LU1057294990.SGD","SG9999002224.SGD","BK4568","SGXZ57979304.SGD","LU0289739699.SGD","IE0002270589.USD","BK4581","LU0058720904.USD","IE00BLSP4452.SGD","SG9999002232.USD","IE00BBT3K403.USD","LU0234572021.USD","IE00B19Z3581.USD","SG9999003800.SGD","LU0306807586.USD","IDYA","IE00BLSP4239.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU1894683264.USD","BK4588","LU1894683348.USD","SG9999011175.SGD","LU0868494617.USD","LU0456855351.SGD","BK4599","SG9999001176.USD","LU1023059063.AUD","LU0122379950.USD","BK4007","LU0225771236.USD","SG9999001176.SGD","BK4534","LU1066053197.SGD","LU0321505868.SGD","LU0321505439.SGD","BK4207","BK4533","LU1883839398.USD","LU0985481810.HKD","LU0306806265.USD","BK4592","LU0225284248.USD"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":30,"code":"91000000","status":"200"}]}}